I-131 as adjuvant treatment for differentiated thyroid carcinoma may cause an increase in the incidence of secondary haematological malignancies: an "inconvenient" truth?

Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2247-2249. doi: 10.1007/s00259-018-4184-z. Epub 2018 Oct 8.

¹ Department of Nuclear Medicine, University Hospital Marburg, Baldinger Straße, 35043, Marburg, Germany. verburg@med.uni-marburg.de.
² Department of Nuclear Medicine and Thyroid Centre, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
³ Academic Department of Nuclear Medicine, Papageorgiou Hospital, Thessaloniki, Greece.
⁴ Department of Nuclear Medicine, Erasus MC, Rotterdam, The Netherlands.
⁵ Department of Nuclear Medicine and Endocrinology, PET-CT Center LINZ, St Vincent's Hospital, Linz, Austria.
⁶ Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
⁷ Department of Nuclear Medicine, Oncology Institute of Vojvodina, Sremska Kamenica, Serbia.
⁸ Department of Nuclear Medicine, University Hospital Marburg, Baldinger Straße, 35043, Marburg, Germany.

No abstract available

Publication types